PHAR
Pharming Group N.V.
Set alert
- YTD
- -30.79%
- 1 year
- -6.93%
- Open
- 12.18
- Prev close
- 12.24
- Mkt cap
- 865.62M
- Vol
- 14.05K
- Avg vol
- 24.59K
- EPS
- 0.32
- P/E
- 38.22
- Div yield
- 0.00%
More statistics
- Low
- 12.09
- High
- 12.31
- Forward P/E
- 216.49
- Beta
- 0.09
- Short ratio
- 0.38
- Inst. own
- 0.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.57
- 200-d avg
- 15.63
- 1y target
- 34.35
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 1.01B
- Trailing P/E
- 74.63
- Forward P/E
- 216.49
- PEG ratio
- 0.00
- Price / sales
- 2.71
- Price / book
- 3.93
- EPS (TTM)
- 0.19
- Beta
- 0.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.34%
- Revenue (TTM)
- 369.49M
- Revenue growth
- -8.40%
- Free cash flow
- 59.02M
- Total cash
- 170.18M
- Total debt
- 116.20M
- Return on equity
- 5.04%
- Shares outstanding
- 70.63M
- Short % of float
- 0.01%
- 50-day average
- 13.57
- 200-day average
- 15.63
Analyst view
Consensus: strong buy
- Target (low)
- 23.40
- Target (mean)
- 34.35
- Target (high)
- 40.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.063.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.10 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.063 | 0.02 | -0.04 | -68.25% |
| May 7, 2026 | Mar 31, 2026 | 0.05 | -0.07 | -0.12 | -240.00% |
| Mar 12, 2026 | Dec 31, 2025 | 0.15 | 0.07 | -0.08 | -53.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.05 | 0.10 | +0.05 | +100.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.10 | 0.06 | +0.16 | +160.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 10, 2026 | Canaccord Genuity | init | — | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 13, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Mar 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 20, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2025 | Oppenheimer | main | Outperform | Outperform |
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- pharming.com
News
- Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
- Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript
- Pharming Group Q3 Earnings Call Highlights
- Pharming Q3 2026 Earnings Call Transcript
- Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
- Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
- Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
- Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday
- Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings
- Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on PHAR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Silverberg Bernstein Capital Management LLC | 0.06% | 41,547 | 589.14K | Jun 29, 2026 |
| Smartharvest Portfolios, LLC | 0.02% | 10,797 | 153.10K | Mar 30, 2026 |
| Morgan Stanley | 0.02% | 11,489 | 162.91K | Mar 30, 2026 |
| Citadel Advisors Llc | 0.01% | 10,189 | 144.48K | Mar 30, 2026 |
| Knoll Capital Management, LLC | 0.01% | 4,057 | 57.53K | Mar 30, 2026 |
| Nalls Sherbakoff Group, Llc | 0.00% | 870 | 12.34K | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.02% | 12,463 | 176.72K | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.00% | 2,093 | 29.68K | May 30, 2026 |